Pazopanib is a VEGFR-, PDGFR-, and KIT-receptor inhibitor, which is clinically active in metastatic ccRCC, according to the results of a phase III study that included 46% of cytokine-pretreated patients (17). Here, KDR is linked to nonpapillary renal cell carcinoma.